The global Cell Therapy CDMO Services market size is predicted to grow from US$ 2278 million in 2025 to US$ 7433 million in 2031; it is expected to grow at a CAGR of 21.8% from 2025 to 2031.
Cell therapy refers to the transfer of new cells, or cells that have been modified in a laboratory to achieve particular characteristics, into the body to prevent or treat a disease. A Contract Development and Manufacturing Organization (CDMO) is a company that provides comprehensive services to pharmaceutical, biotechnology, and medical device companies. CDMOs offer contract services for product development, formulation, manufacturing, packaging, and distribution. Contract development and manufacturing organizations (CDMOs) play a vital role in cell therapy development by offering crucial infrastructure and expertise.This report mainly focuses on cell therapy CDMO services market.
The cell therapy CDMO market is mainly concentrated in the following regions: North America (especially the United States) is the leader in the global cell therapy CDMO market, with advanced technology, a sound regulatory system and a large number of biopharmaceutical companies. The active support of the US FDA for cell therapy has also driven the growth of the market in the region. The European market also performed strongly, mainly due to the EU's support for cell therapy research and development and the regulatory framework of the EMA (European Medicines Agency). The United Kingdom, Germany and Switzerland are the main markets in Europe. The Asia-Pacific region (especially China, Japan and South Korea) is one of the fastest growing markets. The Chinese government's policy support and financial investment in the field of cell therapy, as well as Japan's leading position in regenerative medicine, have driven the rapid development of the market in the region. The markets in Latin America and the Middle East are relatively small, but with the popularization of cell therapy technology and the improvement of medical infrastructure, the market potential in these regions is gradually being released.
Challenges and Opportunities:
Challenges: The manufacturing process of cell therapy products is complex, requires high quality control, and is expensive. In addition, the instability of the global supply chain and the shortage of raw materials may also affect the delivery of CDMO services. Opportunities: With the advancement of technology and the optimization of manufacturing processes, CDMO companies have the opportunity to further expand their market share by providing efficient and low-cost services. In addition, the rise of emerging markets and the growing demand for personalized medicine have also provided new growth points for CDMO companies.
LPI (LP Information)' newest research report, the “Cell Therapy CDMO Services Industry Forecast” looks at past sales and reviews total world Cell Therapy CDMO Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Cell Therapy CDMO Services sales for 2025 through 2031. With Cell Therapy CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Therapy CDMO Services industry.
This Insight Report provides a comprehensive analysis of the global Cell Therapy CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Therapy CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell Therapy CDMO Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Therapy CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Therapy CDMO Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Therapy CDMO Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Preclinical Stage
Clinical Commercialization Stage
Segmentation by Application:
Pharmaceutical Company
Research Institute
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Charles River Laboratories
AGC Biologics
FUJIFILM Cellular Dynamics
Thermo Fisher Scientific
Wuxi AppTec
Lonza
KBI Biopharma
RoslinCT
Cell and Gene Therapy Catapult
Cell Therapies
Minaris Regenerative Medicine
MEDINET
Catalent Biologics
Oxford BioMedica
GenScript
Cell-Easy
SK pharmteco
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook